Xcell Biosciences to Showcase Future of Cell Manufacturing at ISCT 2024
AmplifyBio and Xcell Biosciences Announce Partnership to Manufacture Solid Tumor-Targeting TCR-T Cell Therapy
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
Xcell Biosciences Announces Collaboration with ElevateBio
Pharmaceutical companies Xcell Biosciences (Xcellbio) and aCGT Vector have partnered to expedite the development of cell and gene therapies.
SAN FRANCISCO & DUBLIN--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, today announced a collaboration to improve manufacturing and analytic procedures used to develop personalized cell and gene therapies for cancer patients. Through this alliance, aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s core next-generation manufacturing and analytical AVATAR AI technology for use in precision cancer treatment.
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an automation and instrumentation company focused on cell therapy manufacturing, today announced the appointment of Shannon Eaker, Ph.D., as its Chief Technology Officer. A veteran of the cell and gene therapy industry, Dr. Eaker will be responsible for driving Xcellbio’s instrument and software development strategy and the commercial delivery of its innovative commercial platforms.
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, is collaborating with Xcell Biosciences, Inc. (Xcellbio), a leading developer of cell and gene therapy technologies, to advance critical work that helps clients effectively bring innovative cell and gene therapies to market.